Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab.

ABSTRACT:

Introduction

Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable ongoing trastuzumab) has been shown feasible, the longer-term outcomes are unknown. We aimed to study the intermediate-term clinical outcomes of patients who underwent permissive cardiotoxicity.

Materials and methods

We performed a retrospective cohort study of patients referred to the cardio-oncology service at McMaster University from 2016 to 2021 for LV dysfunction following trastuzumab administration.

Results

Fifty-one patients underwent permissive cardiotoxicity. The median (25th-75th percentile) follow-up time from ca

SUBMITTER: Zhou S 

PROVIDER: S-EPMC10485282 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature